10097-ACT-6 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPANNoriyuki Kijima, Haruhiko Kishima, Tetsuro Tachi et al.|Neuro-Oncology Advances|2023Cited by 1
Calvarial Thickening in Tuberous Sclerosis ComplexHideki Kuroda, Haruhiko Kishima, Naoki Tani et al.|World Neurosurgery|2024Cited by 1
Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastomaHideki Kuroda, Haruhiko Kishima|Cancer Immunology Immunotherapy|2025Cited by 1
ACT-20 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPANNoriyuki Kijima, Haruhiko Kishima, Manabu Kanemoto et al.|Neuro-Oncology Advances|2022Cited by 0